Investor Alert: Pomerantz Law Firm Probes Soleno Therapeutics for Potential Securities Fraud

Pomerantz LLP, a leading law firm known for class litigation, has begun an investigation involving investors of Soleno Therapeutics, Inc. This inquiry comes in light of serious allegations of potential securities fraud and misconduct within the company. Investors affected by the potential discrepancies are encouraged to reach out to Danielle Peyton at Pomerantz for support and information regarding possible claims.

Investigation Details

The focus of the investigation is whether Soleno Therapeutics and certain executives have engaged in illegal practices that could harm investors. Recently, critical reports have surfaced regarding Soleno's flagship product, Vykat XR, which is designed for the treatment of various health issues. On August 15, 2025, Scorpion Capital published a report labeling Vykat XR as overpriced and potentially unsafe for children. This negative publicity has led to significant repercussions, including a sharp drop in the company’s stock prices—falling $5.73, equating to a 7.41% decrease, closing at $71.63 on the same day.

This downturn in the stock value raises concerns among investors about the integrity of Soleno's business practices and the safety of its products. Investors who believe they may have suffered losses due to these developments are strongly advised to participate in the investigation and seek legal recourse if deemed appropriate.

Pomerantz LLP – A Trusted Ally

Pomerantz LLP holds a reputable standing in the realm of securities class actions and has been instrumental in defending investor rights for over eight decades. Founded by the prominent Abraham L. Pomerantz, the firm has developed a robust framework for addressing corporate fraud and misconduct, having successfully secured numerous multimillion-dollar settlements for their clients.

In the wake of these developments, the firm maintains its commitment to investigating the claims against Soleno thoroughly and pursuing necessary legal actions to protect the interests of the investors involved.

For those interested in joining the class action or needing further assistance, Pomerantz recommends that investors contact Danielle Peyton directly at the provided email address or phone number.

Conclusion

As the investigation unfolds, stakeholders and investors must remain vigilant about their investments in Soleno Therapeutics. With the potential for securities fraud casting shadows on the company, monitoring updates and aligning with expert legal advice can be crucial for those impacted. It’s imperative for investors to understand their position and take appropriate actions to safeguard their financial interests.

For more information and assistance, do not hesitate to reach out to Pomerantz LLP, as they are poised to fight for the rights of those affected by potential corporate misconduct.